Novo Holdings is set to purchase Catalent (NYSE:CTLT) for $63.50 per share, valuing the deal at $16.5 billion, which includes the company's enterprise value, as per a recent press release.

Catalent's shareholders will receive a 47.5% premium on the stock's 60-day volume-weighted average price as of Feb 2. Following the announcement, Catalent's stock experienced a more than 9% increase intra-day today.

Targeted to boost patient care by leveraging Catalent's development and supply chain capabilities, the acquisition is expected to be finalized by the end of 2024, subject to the approval of stockholders and the receipt of regulatory clearances.